Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving

  • AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high.
  • Shares have strong technical momentum and a 100% “Buy” opinion from Barchart.
  • Analyst sentiment remains bullish, but Wall Street thinks earnings and revenue will decline next year.
  • More than 30% of the float is sold short, creating another reason for caution with ANAB. 

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.